Undifferentiated and Dedifferentiated Melanoma of the Genitourinary Tract: A Case Series Demonstrating the Potential for Diagnostic Pitfalls

Undifferentiated/dedifferentiated melanomas typically lack all conventional melanocytic biomarkers and closely mimic non-melanocytic malignancies, risking misclassification and missed melanoma-directed therapy. We report four metastatic undifferentiated/dedifferentiated melanomas from 3 women and 1 man (median age 67 years) to genitourinary (GU) sites, involving the adrenal gland (n = 2), kidney (n = 1), and perirenal soft tissue (n = 1). Resected tumors (n = 3; median 5.4 cm) and one biopsy specimen showed high-grade epithelioid and/or spindle-cell morphology with brisk mitotic figures. All four tumors were S100/SOX10/MelanA/HMB45 negative. PAX8 was also negative. In contrast, pan-keratin/CAM5.2/cytokeratin AE1/AE3 and/or p63 showed focal/multifocal staining in all resected tumors. Additional pitfalls included focal weak TFE3 and scattered cathepsin K expression. PD-L1 was diffusely positive (70%-100% of tumor cells) in 2 tested tumors. Targeted next-generation sequencing showed a MAPK-pathway driver in all tumors: BRAF class-3 (D594N, G466R) in 2/4 tumors, NRAS Q61R in 1 tumor, and NF1 truncation (R440*) in 1 tumor, with frequent co-events ( TERT promoter mutations; CDKN2A loss; TP53 mutation). UV mutational signatures and high tumor mutational burden supported cutaneous origin. One patient showed clonal continuity between a prior liver metastasis and the subsequent adrenal gland lesion. All patients received PD-1-based immunotherapy (pembrolizumab n = 3; nivolumab n = 1). Three patients achieved complete responses and remain alive and disease-free (median follow-up 28 months; range, 1.8 months-10.5 years), while one patient was lost to follow-up at 2 months with progressive disease. Accurate recognition of these metastatic tumors enables effective therapy. To our knowledge, this is the first dedicated series of GU-site specific undifferentiated/dedifferentiated melanoma and provides a framework for work-up and management.

Authors

Institutions

Publication Details

Journal
International Journal of Surgical Pathology
Published
2026-07-22
DOI
https://doi.org/10.1177/10668969261470831
Primary Topic
Cutaneous Melanoma Detection and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Undifferentiated and Dedifferentiated Melanoma of the Genitourinary Tract: A Case Series Demonstrating the Potential for Diagnostic Pitfalls

Eleanor Russell‐Goldman, Michelle S. Hirsch, Federico Repetto, Chin‐Lee Wu et al.
International Journal of Surgical Pathology
Cutaneous Melanoma Detection and Management
article

Undifferentiated and Dedifferentiated Melanoma of the Genitourinary Tract: A Case Series Demonstrating the Potential for Diagnostic Pitfalls

Eleanor Russell‐Goldman, Michelle S. Hirsch, Federico Repetto, Chin‐Lee Wu, Lyn M. Duncan, E B Oliva, Dora Dias-Santagata, Andres M. Acosta, Ivan Chebib, Igor Odintsov
article en

Abstract

Undifferentiated/dedifferentiated melanomas typically lack all conventional melanocytic biomarkers and closely mimic non-melanocytic malignancies, risking misclassification and missed melanoma-directed therapy. We report four metastatic undifferentiated/dedifferentiated melanomas from 3 women and 1 man (median age 67 years) to genitourinary (GU) sites, involving the adrenal gland (n = 2), kidney (n = 1), and perirenal soft tissue (n = 1). Resected tumors (n = 3; median 5.4 cm) and one biopsy specimen showed high-grade epithelioid and/or spindle-cell morphology with brisk mitotic figures. All four tumors were S100/SOX10/MelanA/HMB45 negative. PAX8 was also negative. In contrast, pan-keratin/CAM5.2/cytokeratin AE1/AE3 and/or p63 showed focal/multifocal staining in all resected tumors. Additional pitfalls included focal weak TFE3 and scattered cathepsin K expression. PD-L1 was diffusely positive (70%-100% of tumor cells) in 2 tested tumors. Targeted next-generation sequencing showed a MAPK-pathway driver in all tumors: BRAF class-3 (D594N, G466R) in 2/4 tumors, NRAS Q61R in 1 tumor, and NF1 truncation (R440*) in 1 tumor, with frequent co-events ( TERT promoter mutations; CDKN2A loss; TP53 mutation). UV mutational signatures and high tumor mutational burden supported cutaneous origin. One patient showed clonal continuity between a prior liver metastasis and the subsequent adrenal gland lesion. All patients received PD-1-based immunotherapy (pembrolizumab n = 3; nivolumab n = 1). Three patients achieved complete responses and remain alive and disease-free (median follow-up 28 months; range, 1.8 months-10.5 years), while one patient was lost to follow-up at 2 months with progressive disease. Accurate recognition of these metastatic tumors enables effective therapy. To our knowledge, this is the first dedicated series of GU-site specific undifferentiated/dedifferentiated melanoma and provides a framework for work-up and management.

International Journal of Surgical Pathology
Brigham and Women's Hospital (US), Harvard University (US), Massachusetts General Hospital (US), University School (US), Indiana University School of Medicine, Indiana University (US)
Openalex Percentile: Top 11%
Cutaneous Melanoma Detection and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.